Alagille Syndrome Market Trend, Segmentation and Forecast to 2023

Market Analysis 

The global alagille syndrome market is likely to grow at a healthy CAGR between 2018- 2023, states the Market Research Future (MRFR) report. Alagille syndrome, simply put, is a rare genetic disorder that impacts various organ systems of the body, especially kidneys, eyes, skeleton, heart, and liver. It is related to biliary atresia, hepatomegaly, and liver diseases, and liver transplantation may be needed in severe cases.

Neurologic problems, distinctive facial features, heart problems, nutrition problems, liver problems, and others are some of its symptoms. Some of the most effective treatments for alagille syndrome include heart surgery, kidney surgery, liver transplantation, vitamin supplements, biliary diversion procedures, medication, and others.

On the contrary, high treatment costs, lack of awareness about the disease, lack of healthcare budget, limited operating revenue opportunities for R&D, and increasing product recalls are factors that may limit the alagille syndrome market growth over the forecast period. 

Market Segmentation

The MRFR report offers an inclusive segmental analysis of the global alagille syndrome market based on end user, diagnosis, treatment, and symptom. 

By symptom, the alagille syndrome market is segmented into neurologic problems, distinctive facial features, heart problems, nutrition problems, liver problems, and others. 

By treatment, the alagille syndrome market is segmented into heart surgery, kidney surgery, liver transplantation, vitamin supplements, biliary diversion procedures, medication, and others. The medication segment is again segmented into anti-histamine, naltrexone, rifampin, cholestyramine, Ursodeoxycholic. The anti-histamine segment is further segmented into hydroxyzine & others. 

By diagnosis, the alagille syndrome market is segmented into prenatal DNA testing, generic testing, liver biopsy, slit-lamp exam, cardiology exam, X-ray imaging, urinalysis, blood test, and others. 

By end user, the alagille syndrome market is segmented into diagnostic centers, hospitals and clinics, and others. 

Key Players

Leading players profiled in the alagille syndrome market report include Merck & Co., Inc, GlaxoSmithKline Plc, Bristol-Myers Squibb Company, Shire, Pfizer, Inc., Novartis AG, AstraZeneca Plc, Albireo Pharma, Inc., Allergen Plc, Lannett, Teva Pharmaceutical Industries Ltd., and Sanofi AG. Industry players have encompassed strategies such as acquisitions and mergers, new product launch, joint ventures, collaborations, and others to create a niche in the market.

Article source: https://article-realm.com/article/Sports-Recreation/12586-Alagille-Syndrome-Market-Trend-Segmentation-and-Forecast-to-2023.html